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Abstract
Dipeptidyl aminopeptidases (DPAPs) are cysteine proteases that cleave dipeptides from
the N-terminus of protein substrates and have been shown to play important roles in many
pathologies including parasitic diseases such as malaria, toxoplasmosis and Chagas’s dis-
ease. Inhibitors of the mammalian homologue cathepsin C have been used in clinical trials
as potential drugs to treat chronic inflammatory disorders, thus proving that these enzymes
are druggable. In Plasmodium species, DPAPs play important functions at different stages
of parasite development, thus making them potential antimalarial targets. Most DPAP inhibi-
tors developed to date are peptide-based or peptidomimetic competitive inhibitors. Here, we
used a high throughput screening approach to identify novel inhibitor scaffolds that block the
activity of Plasmodium falciparum DPAP1. Most of the hits identified in this screen also
inhibit Plasmodium falciparum DPAP3, cathepsin C, and to a lesser extent other malarial
clan CA proteases, indicating that these might be general DPAP inhibitors. Interestingly, our
mechanism of inhibition studies indicate that most hits are allosteric inhibitors, which opens
a completely new strategy to inhibit these enzymes, study their biological function, and
potentially develop new inhibitors as starting points for drug development.
Introduction
Malaria is a devastating infectious disease caused by parasites of the Plasmodium genus. With
half of the world population at risk, over 200 million clinical cases per year, and half a million
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deaths, malaria remains one of the major global health burdens[1]. Malaria is transmitted
through the bite of Anopheles mosquitoes. Parasites first establish an asymptomatic infection
in the liver where they replicate within hepatocytes. After being released into the blood stream,
they multiply exponentially through multiple rounds of red blood cell (RBC) invasion, asexual
replication, and egress from infected RBCs (iRBCs). A small portion of circulating parasites
develops into male and female gametocytes, which reproduce sexually in the mosquito midgut
after being ingested during a blood meal. Parasites then cross the midgut epithelial, multiply,
and travel to the salivary glands from where they are transmitted to the next human host. The
exponential asexual replication of parasites during the erythrocytic cycle is responsible for all
the symptoms and pathology of malaria, and the stage at which parasites are more likely to
become drug resistance.
Plasmodium parasites have become resistant to most front-line drugs, and resistance to new
treatments such as artemisinin-based combination therapy is quickly emerging[2], thus mak-
ing the identification of novel antimalarial targets extremely urgent[3,4]. Proteases are proven
therapeutic targets for a variety of pathologies, including infectious diseases such as AIDS or
hepatitis C[5,6]. More importantly, proteases play essential roles at all stages of parasite devel-
opment[7]. In particular, dipeptidyl aminopeptidases (DPAPs) have been shown to be impor-
tant during the sexual[8,9] and asexual stages of parasite development[10–12], thus making
them potential drug targets to treat malaria and prevent its transmission. These clan CA cyste-
ine proteases cleave dipeptides from the N-terminal of substrate proteins[13,14]. In addition,
DPAPs have been shown to be druggable targets. The mammalian homologue cathepsin C
(CatC) has been pursued by the pharmaceutical industry[15–18] for the treatment of chronic
inflammatory diseases due to its role in activating proinflammatory serine proteases, such as
neutrophil elastase, granzyme A and B, or cathepsin G[19–22]. Recently, highly specific CatC
inhibitors from GlaxoSmithKline (GSK2793660)[23] and AstraZeneca (AZD-7986)[24] have
been studied in phase I clinical trials.
Three DPAPs are conserved in Plasmodium species. In iRBCs, DPAP1 localizes in the
digestive vacuole where it has been proposed to play an essential role in the later stages of the
hemoglobin degradation pathway[10]. This catabolic proteolytic pathway provides free amino
acids for protein synthesis and liberates space within the iRBC to allow parasite growth. How-
ever, the importance of DPAP1 in this pathway has not been validated genetically. DPAP2 is
only expressed in gametocytes and its knock out (KO) results in a significant reduction of
gamete egress from iRBCs[9]. Finally, using a conditional knockout approach we have recently
shown that DPAP3 activity is critical for efficient RBC invasion[12]. Multiple attempts to
directly KO DPAP1 or DPAP3 in P. falciparum have been unsuccessful strongly indicating
that these proteases are important during the erythrocytic cycle[10,12]. However, in the P. ber-
ghei murine model of malaria, KO of DPAP1 or DPAP3 results in a significant delay in asexual
replication[25–27], thus suggesting that DPAPs are important but not essential in P. berghei.
Overall, very little is known about the molecular function of Plasmodium DPAPs, nor whether
they might perform redundant functions. Therefore, specific inhibitors of these proteases will
be very valuable tools to study their biological function and to validate their potential as anti-
malarial targets.
While we have been able to develop potent DPAP covalent inhibitors, stability, off-target
effects, and/or toxicity issues have prevented us from robustly validate these targets in murine
models of malaria[11]. In an attempt to identify novel DPAP inhibitor scaffolds, we pursued a
high throughput screening (HTS) approach for which we developed an assay to specifically
measure DPAP1 activity in parasite lysates. This assay uses the (PR)2Rho substrate, which we
have shown is exclusively cleaved by DPAP1 in trophozoite lysates[28]. This assay precludes
DPAP allosteric inhibitors identified by HTS
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the need to purify or express DPAP1 and allows the measurement of its activity within a more
biologically relevant environment.
In this study we present the results of this HTS campaign where we identified over one hun-
dred active compounds from a library of more than 100,000 small drug-like molecules. Fol-
low-up studies were performed on 33 hits, including mechanism of inhibition studies for the
most potent inhibitors. Most compounds identified in this study also block the activities of
DPAP3, CatC, and to a lesser extend of falcipains 2 and 3 (FP2 and FP3), thus validating these
new compounds as genuine inhibitors of clan CA proteases. FP2 and FP3 are Plasmodium
endopeptidases at the top of the proteolytic pathway that degrades hemoglobin in the digestive
vacuole. Interestingly, most inhibitors do no inhibit DPAP1 or CatC through a competitive
inhibition model but rather through a partial competitive or partial mixed inhibition model,
which suggests the presence of allosteric regulatory sites.
Materials and methods
Materials and reagents
The synthesis and characterization of the fluorogenic substrates (PR)2Rho[28], VR-ACC[29],
and nVal-nLeu(o-Bzl)-ACC[30] have been previously described. Z-LR-AMC and GR-AMC
were purchased from Sigma. All DPAPs were purified as previously described: DPAP1 was
purified from parasite lysates[29], and bovine CatC from spleen homogenates[31,32]; recom-
binant DPAP3 was expressed in insect cells and purified from culture supernatants[12].
Recombinant FP2 and FP3 were a kind gift from Prof. Phillip Rosenthal (UCSF). Hit com-
pounds selected for follow-up studies were purchased from Vitas M. Lab, Chem Div, SPECS,
and ChemBridge (catalogue numbers are reported in S1 Table).
HTS assay, cherry-picking, and hit validation
HTS was performed in black 384-well plates. The first and last two columns of each plate con-
tained our negative (DMSO) and positive (10 μM JCP410) controls, and the 20 central col-
umns the test compounds at 10 μM. Compounds were first diluted 50-fold into assay buffer
(50 mM sodium acetate, 5 mM MgCl2, 10 mM β-mercaptoethanol, and 0.1% CHAPS, pH 5.5)
from a 10 mM DMSO stock plates. One microliter of this 200 μM intermediate stock plate was
dispensed into the assay plate. Reaction was initiated with 10 μL of a 20 μM stock of (PR)2Rho
in assay buffer, followed by 10 μL of trophozoite lysates diluted 1:50 in assay buffer. After 30
min, the reaction was quenched with 20 μL of 0.5 M acetic acid, and the fluorescent intensity
measured at 523 nm (λex = 492 nm) using an Analyst HT multimode plate reader (Molecular
Devices). Test compounds were transferred to the intermediate stock plates and assay plates
with a BioMek FXP automated liquid handler (Beckman Coulter). Assay reagents were added
using a Matrix Wellmate bulk dispenser (Thermo Scientific).
Z’ values were calculated for each of the 333 plates used to screen the library. 227 com-
pounds (> 50% inhibition) were cherry-picked from the 10 mM stock plates, and DPAP1 inhi-
bition confirmed in a dose dependent manner using the same end-point assay. Thirty-seven
compounds were purchased for follow-up studies. To confirm that the purchased compounds
were indeed DPAP1 inhibitors, dose response studies were performed at 10 μM (PR)2Rho
both in parasite lysates and with purified DPAP1 but using a continuous assay rather than an
end-point assay in a SpectraMax 5e (Molecular Devices) multimode platereader. Purified
DPAP1 was used at 1 nM.
DPAP allosteric inhibitors identified by HTS
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Dose response inhibition assays
Each protease was used at 1 nM in the HTS assay buffer described above. Dose response inhi-
bition studies to obtained IC50 values for each of the proteases tested were performed using
fluorogenic substrates at the Km concentrations determined under our assay conditions:
VR-ACC for DPAP1 (Km,DPAP1 = 20 μM)[29], nVal-nLeu(o-Bzl)-ACC for DPAP3 (Km,DPAP3
= 1.4 μM)[30], GR-AMC for CatC (Km,CatC = 40 μM), and Z-LR-AMC for the FPs (Km,FP2 =
5 μM; Km,FP3 = 20 μM). For all assays, substrate turnover was measured for 30 min at 460 nm
(λex = 355nm) using a SpectraMax M5e (Molecular Devices) multimode plate reader. Each
dose response was performed in triplicate with inhibitor concentrations ranging between 0.01
and 50 to 200 μM depending on compound solubility. Initial velocity as a function of inhibitor
concentration was fit to Eq. 1 in GraphPad Prism to obtain IC50 values.
Vi
V0
¼ 1   Dð Þ þ
D
1þ
IC50
½I�
� �HC Eq 1
Vi and V0 are the initial velocities in the presence or absence of inhibitor, respectively, Δ, the
maximum inhibition fraction, and HC, the Hill coefficient. Note that the maximum % inhibi-
tion is equal to 100 x Δ.
Mechanism of inhibition studies
Mechanism of inhibition (MOI) studies were performed in 384-well black plates. For each
compound and enzyme, we measured a matrix of initial velocities using 4–6 concentrations of
substrate (0.25–8 x Km) by 6–8 concentrations of inhibitor (0–100 μM). At each inhibitor con-
centration the dependence of initial substrate turnover on substrate concentration was fitted
to the Michaelis Menten equation to obtain Km,app and Vmax,app. The dependency of these
parameters on inhibitor concentration was examined to select the most appropriate inhibition
model. Initial velocities as a function of substrate and inhibitor concentrations were globally
fitted to the chosen MOI model using GraphPad Prism. The kinetic and inhibition parameters
from these global curve fits were then used to predict the dependence of Km,app and Vmax,app
on inhibitor concentration. This allowed us to visualize how well this predicted Km,app and
Vmax,app values matched those independently determined at each inhibitor concentration. To
statistically validate the chosen inhibition model, we performed F-test null-hypothesis tests in
GraphPad Prism.
Tryptophan fluorescence studies
CatC (2 μM) was incubated for 30 min in assay buffer with DMSO or 20 μM of JCP410, a very
potent covalent inhibitor of CatC (ki/Ki = 5.8x106 M-1s-1)[30]. The enzyme was then diluted
2-fold in assay buffer containing different concentrations of inhibitors. Emission spectra were
measured between 300–400 nm (λex = 280 nm) using a SpectraMax M5e multimode plate
reader (Molecular Devices) in black 96-well plates. Fluorescence intensity at the maximum
emission wavelength (335 nm) was plotted as a function of inhibitor concentration.
Parasite culture and replication assay
Anonymized human blood used to culture malaria parasites was sourced from the United
Kingdom National Health Service Blood and Transplant Special Health Authority. No ethical
approval is required for its use. P. falciparum D10 parasites were cultured in RPMI-based
media supplemented with Albumax as previously described[33]. Parasite cultures were
DPAP allosteric inhibitors identified by HTS
PLOS ONE | https://doi.org/10.1371/journal.pone.0226270 December 18, 2019 4 / 21
synchronized by treating ring stage parasites with sorbitol every 48 h. Trophozoite pellets were
obtained by collecting iRBCs at 24–30 h post invasion, lysing the RBC and parasitophourous
vacuole membranes with saponin, and storing the parasite pellets at -80˚C. These were then
lysed by adding 2 volumes of 1% NP40 in PBS and incubating the samples in ice for 1 h. The
soluble fraction was collected after a 10 min spin at 13,000 rpm in a microcentrifuge, frozen in
liquid N2, and stored at -80˚C. For replication assays, ring stage parasites at 1% parasitemia
and 1% hematocrit were treated with different concentrations of compound for 72 h. After fix-
ation with 0.01% glutaraldehyde, samples were permeabilized for 10 min with 0.1% Triton X,
and DNA stained with propidium iodide. The percentage of iRBCs in each sample was quanti-
fied by FACS as previously described[11]. Three biological replicates were performed for each
compound.
Cytotoxicity assay
Human foreskin fibroblasts were cultured in flat bottom 96-well plates and were treated for
24h one day before they reached confluency with different concentrations of compound. Cell
viability was measured using the Promega CellTiter-Glo Assay using the manufacturer’s
instructions. Cytotoxicity EC50 values were estimated by fitting the data to a dose response
curve. Four biological replicates were performed for this experiment.
Results
HTS against DPAP1 in parasite lysates
We screen two different libraries of compounds: the UCSF Small Molecule Discovery Center’s
Diversity Collection, which is composed of 104,121 compounds and was assembled from
numerous commercial vendors (ChemBridge, ChemDiv and SPECS), and the Celera Protease
Inhibitor Collection of 1,817 compounds, which is unique and not commercially available.
The latter is composed entirely of compounds synthesized by medicinal chemists at Celera
Genomics in the course of various discovery campaigns targeting human cathepsins, primarily
cathepsins K, S, and B. A total of 105,938 small molecules were screened at 10 μM in 384-well
plates using an endpoint assay. Briefly, parasite lysates were diluted in assay buffer and incu-
bated with a mixture of compound and (PR)2Rho for 30 min before quenching the reaction
with acetic acid. The level of substrate cleavage was measured by fluorescence at 523 nm (λex =
492 nm). JCP410, a well-characterized vinyl sulfone covalent inhibitor of DPAP1[33], and
DMSO were used as positive and negative controls, respectively. Normalized DPAP1 activity
for the full screen and the distribution of Z’-values across all plates are shown in Fig 1A and
1B, respectively. The average Z’-value for the full screen was 0.87, which attests to the robust-
ness of the assay. The HTS results and the compounds structures are reported in S2 Table.
Overall, we identified 1077 compounds that significantly decreased DPAP1 activity, i.e. more
than three standard deviations below the average DMSO control activity value (> 20% inhibi-
tion). The 227 most active compounds (> 50% inhibition at 10 μM) were cherry-picked for
validation studies.
Selected compounds were tested between 0.02 and 50 μM using the same endpoint assay
used in the initial screen. Fifty-eight percent showed a concentration dependent inhibition
effect and were considered validated hits (Fig 1C). Thirty seven were purchased for follow-up
studies based on their potency, structural diversity, and commercial availability (S1 Table): 32
correspond to hit compounds identified in the initial screen, 2 are analogues of validated hits
that were no longer commercially available (SMDC153437A and SMDC168384A), and 3 are
structurally related to a family of compounds that showed a very high hit-rate during the
screen (SMDC170123, SMDC170136, SMDC170156), namely 3,8-disubstituted 6-oxo-
DPAP allosteric inhibitors identified by HTS
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pyridothialazine-9-carbonitriles (DOPTACN). Note that 70 DOPTACN compounds were
present in the HTS library; 61 significantly inhibited DPAP1 (> 20% inhibition), and 27
decreased its activity by more than 50% (S3 Table).
Validation of active compounds
To validate that the purchased compounds are DPAP1 inhibitors, they were tested between
0.01 and 100 μM both in trophozoite lysates or with purified DPAP1 using 10 μM (PR)2Rho in
a continuous rather than an end-point assay. Four of the 37 purchased compounds were not
able to inhibit DPAP1 at 100 μM and were considered false positives (Fig 1C and S1 Table).
Characterization of DPAP1 inhibitor hits
(PR)2Rho is not an optimal substrate to determine accurate inhibition constants (Ki) because it
needs to be cleaved twice to release the highly fluorescent rhodamine group28. Therefore, its
turnover by DPAP1 does not follow classical Michaelis Menten behavior. Instead, we used the
VR-ACC DPAP substrate[29] for follow-up studies using purified DPAP1. The 33 validated
inhibitors were first tested at 100 μM against DPAP1 using Km concentrations of VR-ACC
(20 μM). IC50 values were measured for the 19 most potent inhibitors (> 30% inhibition at
100 μM). Six of these are DOPTACN compounds, the structure of which are shown in Fig 2.
The structure of the remaining hit compounds are shown in Fig 3. Interestingly, most com-
pounds were not able to fully inhibit DPAP1, and the maximum level of DPAP1 inhibition
Fig 1. DPAP1 HTS and triage. (A) Screening results. More than 100,000 small molecules were screened at 10 μM in
parasite lysates. DPAP1 activity was measured using the DPAP1-specific fluorogenic substrate (PR)2Rho in an end-
point assay. Normalized activity is shown for each compound (black) and for the positive (10 μM JCP410, red) and
negative controls (DMSO, blue). The green line indicates the 50% inhibition cut-off that was applied to cherry-pick
individual compounds for further studies. (B) HTS performance. Distribution of Z’-values for the 333 plates used in
the screen is shown for an interval of 0.025. (C) Triage process. Our initial screen in parasite lysates identified 227
compounds that inhibited DPAP1 by more than 50% at 10 μM. 131 showed a dose response behavior between 0.02 and
50 μM using the same end-point assay. 37 compounds were purchased for further studies. Four were found to be false
positives while the remaining 33 inhibited purified DPAP1 in a dose-dependent manner using the (PR)2Rho substrate
both in parasite lysates and against purified DPAP1. Compounds that inhibited purified DPAP1 by more than 30% at
100 μM using the VR-ACC substrate were studied in detail, and the mechanism of inhibition (MOI) determined for 12
of them.
https://doi.org/10.1371/journal.pone.0226270.g001
Fig 2. Structure of DOPTACN hits. The structure of the compounds reported in Table 1 are shown.
https://doi.org/10.1371/journal.pone.0226270.g002
DPAP allosteric inhibitors identified by HTS
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ranged between 40 and 100% (Fig 4A and Tables 1 and 2). This partial inhibition behavior
indicates that these molecules do not bind at the same site as the substrate.
Some DPAP1 inhibitors block parasite replication
The antimalarial activity of the 19 most potent DPAP1 inhibitors was first tested at 100 μM
using a standard 72 h parasite replication assay against P. falciparum (Tables 1 and 2). Ten
compounds decreased parasitemia by more than 50% and were further tested in a dose-depen-
dent manner (S1 Fig). The EC50 for most of these compounds ranged between 4 and 35 μM
(Tables 1 and 2). However, there is no clear correlation between IC50 and EC50 values. In order
to inhibit DPAP1, compounds have to cross four membranes (RBC, parasitophorous vacuole,
cytosolic, and digestive vacuole membranes). Also, sustained inhibition of DPAP1 for several
hours is likely necessary to block parasite replication[11]. Therefore, differences in cell perme-
ability and compound stability might account for this lack of correlation. Further studies will
be necessary to determine whether the antimalarial properties of these compounds are due to
DPAP1 inhibition, inhibition of other clan CA proteases, or other off-target effects. However,
we did not think that the antiparasitic activity of these compounds is due to general toxicity
since none of them kill mammalian cell at 10 μM (S2 Table).
To test this hypothesis we performed cell viability assays in human foreskin fibroblast
(HHF) using the CellTiter-Glo Assay (Promega) that measures ATP content within cells. HFF
cells were treated for 24h with different concentrations of compounds (0.2–200 μM), those for
which antiparasitic EC50 values could be obtained (9 compounds). Four biological replicates
were performed, and the data was fitted to a dose response curve (S2 Fig) to obtain cytotoxicity
EC50 values (reported in Tables 1 and 2). For all compounds, the toxicity EC50 values were
above 50 μM, and for most of them the specificity index (measured as the ratio between the
Fig 3. Structure of other validated hit compounds. The structure of the compounds reported in Table 2.
https://doi.org/10.1371/journal.pone.0226270.g003
DPAP allosteric inhibitors identified by HTS
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cytotoxicity and antiparasitic EC50 values) was above 10, with SMDC178790 having the highest
specificity index (S.I. = 50). Overall, all compounds are more potent at killing P. falciparum
parasites than human cells. However, the fact that they all kill human cells at high micromolar
concentrations suggests that their antiparasitic activity might also be due to some general cyto-
toxic effects. That said, as is shown below, most DPAP inhibitors identified in this screen
inhibit other clan CA malarial proteases (falcipains 2 and 3), as well as mammalian CatC.
Fig 4. Dose response inhibition curves for hit compounds. The inhibitory effect of purchased compounds against
DPAP1 (A), DPAP3 (B), CatC (C), FP2 (D) or FP3 (E) was tested at different compound concentrations using
different fluorogenic substrates. Substrates were used at the Km concentration of each enzyme to obtain comparable
IC50 values. Protease activity was normalized to the DMSO control. Each dose-response was fitted to Eq 1. Structurally
related DOPTACN compounds are shown on the left graphs. Compounds for which solubility issues prevented us
from obtaining a maximum inhibition baseline for DPAP1 are show on the right graphs. The remaining compounds
are presented in the middle graphs. IC50 and maximum percentage inhibition values are reported in Tables 1 and 2. All
dose-response were performed in triplicate. Error bars represent standard errors.
https://doi.org/10.1371/journal.pone.0226270.g004
DPAP allosteric inhibitors identified by HTS
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Therefore, the cytotoxicity might also be due to inhibition of multiple human Clan CA prote-
ases in HFFs. Overall, these results indicate that much more potent and DPAP specific inhibi-
tors need to be developed from these inhibitor scaffolds to rule out general cytotoxic effects
and to validate that their antiparasitic activities are mediated through DPAPs inhibition.
Selectivity of DPAP1 inhibitors against other Cys proteases
To determine the specificity of the 19 selected DPAP1 inhibitors against other cysteine proteases,
we tested them against DPAP3, bovine CatC, FP2 and FP3 using different fluorogenic substrates
(Fig 4B–4E). In order to obtain comparable IC50 values, the substrate concentration was fixed to
the Km value determined under our assay conditions for each protease:substrate pair. All IC50
and maximum percentage inhibition values are reported in Tables 1 and 2. Most compounds
were able to inhibit all proteases, but we observed significant differences in potency (IC50) and
maximum level of inhibition between the different proteases. This indicates that the observed par-
tial inhibition effects are not due to compound concentration effects such as aggregation, instabil-
ity, or assay interference. Note that only one of the hit compounds, SMDC31843, was identified
as a potential pan-assay interference (PAIN) compound[34]. Also, none of the hit compounds
was able to inhibit caspase 2 or 6 by more than 50% at 10 μM, as determined in previous HTS
campaigns performed at the SMDC (S1 Table). Overall, this suggests that the compounds identi-
fied in this screen are clan CA protease inhibitors rather than highly promiscuous compounds.
Based on previous screens of peptidic or peptidomimetic inhibitors, it has been relatively
difficult to identify compounds that discriminate between DPAP1 and DPAP3 or between FP2
and FP3[11,33]. However, most DPAP1 inhibitors identified in this screen are relatively poor
DPAP3 inhibitors (Fig 4A and 4B and Tables 1 and 2). For example the DOPTACN com-
pound achieve higher levels of maximum inhibition for DPAP1 (60–83%) than for DPAP3
(10–20%), and SMDC153437A and SMDC168313 are at least 100-fold more potent for
Table 1. IC50 and EC50 values for DOPTACN hit compounds.
SMDC# IC50 (μM)
&
Maximum % Inhibitiona
Pf EC50 (μM)b
&
% Inh @ 100 μM
Tox EC50 (μM)c
&
S.I.
DPAP1 DPAP3 CatC FP2 FP3
170123 0.74 (0.05)
78 (2)
1.0 (0.3)
11 (2)
0.12 (0.03)
48 (3)
~35 (4)
>50
0.093 (0.007)
83 (4)
>100
64 (9)
N.D.
170136 1.3 (0.1)
83 (2)
0.9 (0.2)
10 (1)
0.07 (0.01)
65 (2)
0.21 (0.02)
98 (2)
0.10 (0.01)
99 (3)
14 (2)
79 (3)
180 (20)
13
170156 1.1 (0.1)
73 (2)
0.9 (0.3)
19 (2)
0.62 (0.07)
65 (2)
9.0 (1.5)
100 (10)
0.61 (0.04)
95 (5)
31 (6)
66 (3)
240 (50)
8
178790 0.84 (0.07)
60 (2)
0.40 (0.08)
18 (1)
0.33 (0.06)
66 (3)
0.9 (0.1)
98 (2)
0.27 (0.04)
92 (4)
4 (2)
74 (5)
200 (50)
50
178801 0.9 (0.1)
75 (3)
0.23 (0.04)
20 (1)
0.11 (0.02)
48 (2)
17 (10)
80 (15)
0.069 (0.004)
93 (4)
31 (7)
78 (2)
52 (9)
1.7
178822 0.65 (0.07)
82 (2)
0.16 (0.03)
16 (1)
0.12 (0.02)
48 (3)
12 (4)
100 (8)
0.080 (0.006)
99 (1)
28 (6)
78 (5)
100 (25)
3.6
a When we could not obtain a maximum inhibition baseline, an approximate IC50 value is given (~ sign) as the concentration where we observed 50% inhibition. The
maximum level of inhibition obtained at the highest concentration is also reported (> sign).
b In vitro antiparasitic activity against P. falciparum was determined using a standard 72h replication assay (3 biological replicates).
c Cytotoxicity EC50 values were determined in human foreskin fibroblast cells using the CellTiter-Glo Assay from Promega (4 biological replicates). The specificity index
(S.I.) was calculated by dividing the cytotoxicity EC50 value by the P. falciparum antiparasitic EC50 value.
All experiments were performed in triplicate. Standard errors are shown in parentheses.
https://doi.org/10.1371/journal.pone.0226270.t001
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DPAP1 than DPAP3 (IC50,DPAP1 = 0.27 μM vs. IC50,DPAP3 = 100 μM and IC50,DPAP1 = 1.8 μM
vs. IC50,DPAP3 >> 100 μM, respectively). Also, several compounds show more than 50-fold
selectivity towards FP3 compared to FP2 (Fig 4D and 4E and Tables 1 and 2) such as SMDC1
53437A (IC50,FP2 ~ 100 μM vs. IC50,FP3 = 2.3 μM) or some DOPTACN compounds (SMDC170
123: IC50,FP2 ~ 35 μM vs. IC50,FP3 = 0.093 μM; SMDC178801: IC50,FP2 = 17 μM vs. IC50,FP3 =
0.069 μM; SMDC178822: IC50,FP2 = 12 μM vs. IC50,FP3 = 0.08 μM).
DOPTACN compounds show partial inhibition of all DPAPs but full inhibition of the falci-
pains with the exception of FP3 inhibition by SMDC170123 (80% inhibition). The fact that this
family of compound achieves different levels of maximum inhibition for different proteases
(10–20% for DPAP3, 45–65% for CatC, 60–85% for DPAP1, and 80–100% for the FPs) suggests
a conserved allosteric partial inhibition mechanism. Although we observed relatively flat SAR
for this compound family against DPAP1, this was not the case for other proteases, thus indicat-
ing that these compounds might bind into a specific pocket rather than through a non-specific
Table 2. IC50 and EC50 values for hit compounds.
SMDC # IC50 (μM)
&
Maximum % Inhibitiona
Pf EC50 (μM)b
&
% Inh @ 100 μM
Cytox EC50 (μM) c
&
S.I.
DPAP1 DPAP3 CatC FP2 FP3
153437A 0.27 (0.02)
78 (1)
25 (7)
100 (15)
1.2 (1.5)
47 (8)
~100
>60
2.3 (0.5)
100 (4)
N.D.
28 (2)
N.D.
168313 1.8 (0.2)
78 (2)
N.I. ~100
>50
~50
>85
6.3 (0.5)
100 (7)
N.D.
20 (1)
N.D.
31843PAIN 2.2 (0.2)
71 (2)
30 (8)
100 (14)
~25
>75
~100
>70
5.7 (0.8)
100 (4)
N.D.
24 (3)
N.D.
39848 34 (7)
94 (6)
~100
>50
~100
>50
N.I. N.I. N.D.
13 (1)
N.D.
97214 7.2 (0.5)
100 (3)
~100
>70
0.11 (0.01)
78 (1)
0.25 (0.02)
96 (2)
0.68 (0.08)
97 (3)
N.D.
32 (4)
N.D.
158691 18 (8)
88 (12)
N.I. 9(3)
91 (9)
1.00 (0.03)
100 (3)
2.50 (0.04)
100 (4)
9 (1)
88 (3)
70 (8)
8
168314 200 (80)
100
~100
>50
N.I. N.I. N.I. N.D.
35 (5)
N.D.
106517 5.7 (0.6)
67 (2)
21 (3)
100 (8)
~100
>50
~100
>80
7.2 (0.8)
100 (8)
15 (3)
83 (5)
160 (40)
11
106958 80 (50)
85 (2)
~100
>50
~100
>50
~100
>80
6.5 (0.6)
100 (5)
N.D.
25 (2)
N.D.
111619 ~ 100
> 50
N.I. ~50
>80
21 (5)
100 (7)
18 (5)
100 (10)
N.D.
35 (4)
N.D.
103222 1.7 (0.3)
51 (2)
~50
>75
1.4 (0.3)
91 (4)
20 (3)
36 (3)
15.9 (0.8)
94 (1)
23 (8)
75 (2)
400 (120)
17
112370 0.6 (0.2)
42 (3)
31 (6)
100 (10)
13.5 (1.5)
64 (3)
~50
>80
21 (3)
100 (6)
N.D.
6 (1)
N.D.
112054 2.7 (0.1)
100 (1)
>100
>35
0.9 (0.1)
100 (3)
0.95 (0.02)
95 (2)
0.52 (0.04)
100 (2)
35 (5)
83 (9)
350 (100)
10
a When we could not obtain a maximum inhibition baseline, an approximate IC50 value is given (~ sign) as the concentration where we observed 50% inhibition. The
maximum level of inhibition obtained at the highest concentration is also reported (> sign).
b In vitro antiparasitic activity against P. falciparum was determined using a standard 72h replication assay (3 biological replicates).
c Cytotoxicity EC50 values were determined in human foreskin fibroblast cells using the CellTiter-Glo Assay from Promega (4 biological replicates). The specificity index
(S.I.) was calculated by dividing the cytotoxicity EC50 value by the P. falciparum antiparasitic EC50 value.
PAIN Only one hit compound in which we performed follow-up study (SMDC31843) was identified as a PAIN molecule.
All experiments were performed in triplicate. Standard errors are shown in parentheses.
N.I. No inhibition. N.D. Not determined because treatment at 100 μM show no significant decrease in parasitemia.
https://doi.org/10.1371/journal.pone.0226270.t002
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Fig 5. Representative cases of different mechanisms of inhibition. Based on our MOI studies, all compounds inhibit the
different proteases tested via one of six different inhibition models. A representative data set for each of these MOIs is shown
in each panel: (A) competitive (Eq 3), (B) partial competitive (Eq 6), (C) uncompetitive (Eq 4), (D) partial uncompetitive (Eq
7), (E) partial non-competitive (Eq 8), and (F-H) partial mixed inhibition (Eq 9). Three different case of partial mixed
inhibition are shown: inhibitor decreases Vmax,app and increases Km,app (F), inhibitor decreases Vmax,app and Km,app (G), and
inhibitor increases Vmax,app and Km,app (H). The big graph in each panel shows the global fit of the data set (a matrix of initial
velocities containing 4–6 substrate concentrations by 6–8 inhibitor concentrations) to the appropriate inhibition model.
DPAP allosteric inhibitors identified by HTS
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mechanism (Fig 4 and Tables 1 and 2). Interestingly, this class of compounds is consistently
more potent against DPAP3 or CatC than against DPAP1 or the FPs (IC50 values), but they
achieve lower levels of maximum inhibition. Enzyme dependent effects were also observed for
other compounds: SMDC97214 fully inhibits DPAP1 and the FPs but only achieves 80% inhibi-
tion of CatC, SMDC153437A fully inhibits DPAP3 and FP3 but only inhibits DPAP1 by 80%;
and SMDC103222 inhibits DPAP1, CatC and FP3 by 50, 90, and 100%, respectively.
Mechanism of inhibition studies
To better understand this partial inhibition effect, we performed MOI studies for 12 com-
pounds that showed IC50 values below 10 μM for DPAP1. MOI studies for CatC and FP3 were
also conducted with selected compounds. For each compound and protease initial turnover
rates at different substrate and inhibitor concentrations were measured (Fig 5). Apparent Vmax
and Km values (Vmax,app and Km,app) were calculated at each inhibitor concentration (Fig 6, Eq
2). We then examined the dependence of these parameters on inhibitor concentration to
determine the appropriate MOI model (Fig 6): full or partial competitive (increase in Km,app,
Fig 6 Eqs 3 and 6, Fig 5A and 5B), full or partial uncompetitive (equal decrease in Vmax,app and
Km,app, Fig 6 Eqs 4 and 7, Fig 5C and 5D), full or partial non-competitive (decrease in Vmax,app,
Fig 6 Eqs 5 and 8, Fig 5E), or partial mixed inhibition (changes in Vmax,app and Km,app, Fig 6 Eq
9, Fig 5F–5H). Each data set was then globally fitted to the appropriate MOI model using
GraphPad Prism. Fig 5 shows a representative data set for each MOI model. All other MOI fits
are shown in S3 Fig. To statistically justify which one of these models better fitted our data, we
performed null-hypothesis F-tests using GraphPadPrism as reported in S4 Table. All inhibi-
tion parameters (Ki, α, and Δ) are reported in Table 3; α and β indicate the factor by which Km
and kcat are modified at saturating inhibitor concentrations, respectively.
Most compounds showing partial inhibition behavior increased Km,app (1.3 < α< 5.6) and/
or decrease Vmax,app (0.09 < β< 0.85). However, for several compounds we observed a 40–
70% increase in Vmax,app (β> 1 for inhibition of DPAP1 by SMDC170123 or of CatC by
SMDC153437A) or a 60–80% decrease in Km,app (α< 1 for inhibition of CatC by SMDC31843
or of FP3 by SMDC178801 and SMDC170123). This increase in substrate affinity (Km,app) or
maximum turnover rate (Vmax,app) upon inhibitor binding provides strong evidence of alloste-
ric effects and raises the possibility that structurally related compounds might act as allosteric
activators. Indeed, Fig 5H clearly shows that at saturating concentrations of substrate,
SMDC153437A increases the activity of CatC. Finally, inhibition of FP3 by SMDC103222 and
SMDC31843 is consistent with an uncompetitive inhibition model, indicating that this com-
pound likely binds the enzyme-substrate complex.
Although structurally related compounds seem to inhibit a specific enzyme through differ-
ent MOIs, or a single inhibitor inhibits different enzymes via different MOIs, it is important to
mention that all inhibition models except uncompetitive inhibition can be explain as particular
cases of the partial-mixed inhibition model. The values of the α and β parameters indicate the
factor by which Km and kcat are modified upon inhibitor binding, respectively (Fig 6). There-
fore, for competitive inhibition, α =1; for partial competitive, β = 1; for partial non-
Inhibition concentrations in the legend are in micromolar. The small graphs show the independently obtained Km,app and
Vmax,app values at each inhibitor concentration. The lines in these graphs represent the predicted dependence of Km,app and
Vmax,app on inhibition concentration calculated based on the inhibition parameters obtained from the global data fit using
the equations reported in the S5 Table. Error bars in the small graphs represent the standard error of the fit obtained for Km,
app and Vmax,app.
https://doi.org/10.1371/journal.pone.0226270.g005
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competitive, α = 1; and for partial uncompetitive, α = β. Note that allosteric activators would
decrease Km (α< 1) and/or increase kcat (β> 1).
Selected CatC inhibitors induce conformational changes independently of
active site occupancy
To determine whether some of the identified inhibitors induce a conformational change upon
binding, we measured the intrinsic tryptophan fluorescence emission spectra of CatC in the
presence of four different inhibitors (SMDC103222, SMDC112054, SMDC153437A, and
SMDC178822). As shown in Fig 7, these four compounds decrease the maximum level of Trp
fluorescence in a dose dependent manner. More importantly, these changes in Trp fluores-
cence were also observed in the presence of JCP410, an irreversible inhibitor that covalently
modifies the catalytic Cys of CatC. Overall, these results provide further evidence that these
compounds do not bind into the active sites of DPAPs, and that they are likely acting through
an allosteric mechanism. However, it is important to mention that the fluorogenic substrates
or the covalent inhibitor used in our studies do not bind beyond the S2’ pockets. Therefore, we
cannot rule out the possibility that some of these compounds might influence substrate turn-
over by binding into the S3’-S4’ pockets (in which the case, some of these compounds might
act as competitive inhibitors of natural substrates).
Discussion
Our HTS approach in parasite lysates has identified a variety of novel compound scaffolds that
inhibit not only DPAPs but also other clan CA cysteine proteases. Surprisingly, most hits iden-
tified in this study seem to be allosteric inhibitors. A possible explanation for this result might
be the fact that the screen was performed in parasite lysates. DPAPs cleave dipeptides from the
Fig 6. Mechanism of inhibition models. The name of inhibition model, a schematic of the enzyme reaction under steady-
state kinetics conditions, and the equation describing each model as a function of Vmax, Km, Ki, alfa, and beta are shown.
Alfa is the factor by which Km is modified upon inhibitor binding, and beta the factor by which Vmax is modified upon
inhibitor binding.
https://doi.org/10.1371/journal.pone.0226270.g006
Table 3. Mechanism of inhibition studies results.
DPAP1 CatC FP3
SMDC # Model Ki (μM) α β Model Ki (μM) α β Model Ki (μM) α β
112054 COM 0.44 (0.07) =1 0 < β <1 N.D. N.D.
97214 COM 3.0 (0.3) =1 0 < β <1 N.D. N.D.
31843 P-C 6.2 (0.9) 5.6 (0.7) = 1 P-M 140 (50) 0.33 (0.06) 0 (0.04) UNC 14.2 (0.1) N.A.
103222 P-C 1.1 (0.2) 2.12 (0.09) = 1 N.D. UNC 9.1 (0.6) N.A.
168313 P-C 4.1 (0.6) 2.8 (0.2) = 1 N.D. N.D.
170136 P-C 1.4 (0.3) 2.3 (0.1) = 1 P-NC 0.8 (0.2) = 1 0.56 (0.02) P-U 12 (4) 0.07 (0.02)
170156 N.D. P-NC 3.7 (0.9) = 1 0.52 (0.04) N.D.
178790 P-C 0.40 (0.07) 2.7 (0.2) = 1 N.D. N.D.
178801 P-C 0.36 (0.06) 3.2 (0.2) = 1 N.D. P-M 6.6 (2.5) 0.22 (0.09) 0.09 (0.03)
170123 P-M 1.3 (0.4) 4.3 (1.3) 1.4 (0.3) P-NC 0.95 (0.3) = 1 0.66 (0.03) P-M 3.8 (0.9) 0.38 (0.09) 0.23 (0.03)
106517 P-M 1.0 (0.3) 1.3 (0.2) 0.85 (0.05) N.D. N.D.
153437A P-M 0.06 (0.02) 4.0 (1.5) 0.35 (0.05) P-M 2.4 (1) 2.6 (0.6) 1.7 (0.1) N.D.
Inhibition models: COM, competitive (Eq 3); UNC, uncompetitive (Eq 4); P-M, partial mixed (Eq 9); P-C, partial competitive (Eq 6); P-NC, partial non-competitive (Eq
8); P-U, partial uncompetitive (Eq 7). N.D., Not determined; N.A. Not Applicable. Standard errors of the fit for each parameter are shown in parentheses.
https://doi.org/10.1371/journal.pone.0226270.t003
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free N-terminus of proteins and peptides. Because the screen was performed under acidic con-
ditions, most proteases that are usually found in the digestive vacuole (four aspartyl proteases
Fig 7. Effect of inhibitor binding on Trp fluorescence emission. The Trp emission spectra (λex = 280 nm) obtained
after treating 1 μM of CatC with different concentrations of four different inhibitors are shown before (left graphs) and
after (middle graph) pre-incubation of CatC with JCP410, a potent covalent inhibitor of CatC. (A) SMDC103222, (B)
SMDC112054, (C) SMDC153437A, and (D) SMDC178822. In all cases, compound binding decreased Trp
fluorescence emission. Dose response curves at the maximum emission wavelength (335 nm) are shown on the right
graphs. Inhibitor concentrations in the legend of the emission spectra graphs are in micromolar.
https://doi.org/10.1371/journal.pone.0226270.g007
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(plasmepsins), three falcipains, falcilysin (metalloprotease), and several aminopeptidases)[7]
were likely active during the course of the assay and would have cleaved a variety of proteins
present in the lysate, thus generating a large abundance of free N-termini. These would have
likely been recognized and cleaved by DPAP1 since this protease has a broad substrate specific-
ity[35]. Screening compounds in the presence of a large number of competitive substrates
might have therefore biased the identification of hits towards inhibitors that do not bind into
the substrate binding pocket. To the best of our knowledge, these are the first allosteric DPAP
inhibitors reported to date. However, allosteric inhibitors have been previously documented
for clan CA proteases. For example, natural products such as heme[36] or suramin[37], and
small molecule chalcone inhibitors[38] have been shown to be allosteric inhibitors of the falci-
pains. Also, allosteric inhibitors have been developed for cathepsin K[39].
There are several advantages in the development of allosteric inhibitors, the most obvious
being that the inhibitor does not need to compete with natural substrates in order to bind its
target. This might be beneficial for inhibiting DPAP1 since this enzyme is likely working
under substrate saturation conditions in the digestive vacuole where a variety of DPAP sub-
strates are being generated continuously by upstream and downstream proteases. Therefore,
sustained inhibition of DPAP1 might be better achieved with allosteric inhibitors than with
reversible competitive inhibitors. Although the use of partial inhibitors is unlikely to be a via-
ble strategy for antimalarial treatment, the structure of these compounds could be optimized
toward 100% inhibition, as is the case for inhibition of FP3 by some of the identified hits. That
said, we cannot rule out the possibility that the partial inhibitors identified here might fully
inhibit the cleavage of natural substrates if they bind into the S3’-S4’ pockets or into an exosite
that might be important for substrate recognition.
Finally, one of the concerns when developing antimalarial drugs is the importance to avoid
off-target inhibition of host homologues, in this case CatC. However, in vivo studies have
shown that full and sustained inhibition of CatC is required to observe a decrease in the activ-
ity of neutrophil elastase, which is activated by CatC[40,41]. Therefore, developing inhibitors
that partially inhibit CatC but fully inhibit Plasmodium DPAPs might be a good strategy to
prevent off-target effects due to CatC inhibition.
To the best of our knowledge the compounds identified in this study are the first reported
allosteric inhibitors for dipeptidyl aminopeptidases. This opens completely new medicinal
chemistry avenues for inhibitor development, either as tools to study the biological function of
these enzymes, or as starting points for drug development. However, their poor antiparasitic
activity and their cytotoxic effects against human cells at high micromolar concentrations indi-
cate that more potent and specific inhibitors need to be designed to determine whether devel-
oping DPAP allosteric inhibitors is a good strategy to generate antiparasitic compounds.
Although DPAPs have been shown to play important functions in both Plasmodium[7] and
Toxoplasma[42] parasites, little is known about their molecular function in these organisms or
in other unicellular pathogens despite being conserved in most eukaryotic organisms. There-
fore, inhibitors developed based on the scaffolds identified in this study might be instrumental
in understanding the role of DPAPs in other pathologies such as Chagas’ disease, leishmania-
sis, African trypanosomiasis and babesiosis.
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S1 Fig. Antiparasitic activity of selected hits. A synchronized culture of P. falciparum at 1%
parasitemia and 1% haematocrit was treated at ring stage with different concentrations of the
indicated compounds and cultured for 72 h. Samples were then fixed, the iRBCs stained with
propidium iodide, and the parasitemia quantified by flow cytometry. Normalized parasitemia
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relative to DMSO controls is shown. EC50 values are reported in Tables 1 and 2.
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S2 Fig. Dose-dependent cytotoxic effects. HFF cells were treated for 24h with different con-
centrations of selected inhibitors. Cell viability was measured using the CellTiter-Glo Assay
(Promega), a biolumniscence-based assay that measures ATP levels within cells. Four biologi-
cal replicates were performed for this experiment. The averaged normalized luminescence sig-
nal was fitted to a dose response curve. The cytotoxic EC50 values are reported in Tables 1 and
2. Error bars represent standard error of the mean.
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S3 Fig. Mechanisms of inhibition studies not shown in Fig 5. The inhibition model used to
globally fit the data is shown above each large graph. As in Fig 5, the Km,app and Vmax,app val-
ues obtained at each inhibitor concentration are shown in the small graphs and the lines in
these graphs represent the predicted dependence of these parameters based on the Ki, α and β
values obtained from the global data fit (reported in Table 3). For each MOI data set, the inhib-
itor and enzyme that were investigated can be seen in the X-axis of the small graph and the Y-
axis of the large graph, respectively. Inhibitor concentrations in the legend of the large graph
are in micromolar. Error bars in the small graphs represent the standard error of the fit
obtained for Km,app and Vmax,app.
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